BINV — BioInvent International AB Income Statement
0.000.00%
Last trade - 00:00- SEK1.93bn
- SEK1.08bn
- SEK44.69m
Annual income statement for BioInvent International AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 147 | 19.4 | 326 | 71.5 | 44.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 223 | 298 | 377 | 441 | 516 |
| Operating Profit | -75.5 | -278 | -50.9 | -370 | -471 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -76.3 | -278 | -42.5 | -330 | -429 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -76.3 | -278 | -42.5 | -330 | -429 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -76.3 | -278 | -42.5 | -330 | -429 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -76.3 | -278 | -42.5 | -330 | -429 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.66 | -5.14 | -0.691 | -5.02 | -6.53 |
| Dividends per Share |